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SUMMARY
This report covers a review of the literature and a descrip-
tion of a double-blind placebo-controlled trial, of 200 mg
of amantadine hydrochloride daily in the treatment of 23
parkinsonian patients. Statistical analysis of clinical results
showed a significant improvement in rigidity and tremor at
rest and a fair improvement in initiating movements and
alertness. Subjective mood elevation was not confirmed by
statistical analysis. Gait, voice control, jaw tremor and
salivation showed no statistical improvement, while eye
convergence may be adversely affected. Side-effects were
minimal. Amantadine hydrochloride (Symmetrel, Geigy)
appears to have real value in the treatment of parkinsonism.
There is growing interest in the effects of amantadine
hydrochloride (l-adamantanamine hydrochloride; Sym-
metrel, Geigy) in parkinsonism. This substance, an antiviral
agent, was first used in the treatment of A-2 (Asian) in-
fluenza.
A patient with parkinsonism, on receiving the drug,
showed unexpected improvement of her neurological dis-
order.' Since then medical interest has been directed to this
aspect of the drug's effect. Amantadine hydrochloride is a
stable, white, crystalline compound, freely water soluble,
and is the salt of a symmetrical lO-carbonamine, with an
unusual cyclic structure. In man, the drug is rapidly ab-
sorbed and there is almost complete recovery of an
administered dose in unaltered form from the urine.' Its
.antiviral effect stems from its ability to alter the host-cell
membrane, thus preventing the virus from entering the
cell. Its effect in parkinsonism is ill understood. Parkes
et al.' suggested that 'amantadine probably has a central
effect but a direct or indirect effect on areas of the central
nervous system, in which dopamine is a recognized trans-
mitter, cannot be inferred at this stage'.
Another possibility is that amantadine acts in an anti-
RNA manner. Stephanis and Issidorides' suggested that
there may be a disturbance of protein synthesis in parkin-
sonism, as well as a disturbance of dopaminergic and
cholinergic activity. They postulated that an unknown
agent stimulates the production of a new messenger-RNA
(mRNA). As a result, the neurone is not capable of syn-
thesizing certain proteins needed in signal transmission.
Issidorides5 submitted that there is an increase in RNA, in-
versely related to melanin content in parkinsonism. He
pointed out that Gonirato and Hyden' found an increase
in aberrant mRNA in the glia of the globus pallidus early
in the disease and that later there was a similar increase
in RNA in the neurones of the same area.
To test their hypothesis Stephanis and Issidorides used
chloramphenicol, a known inhibitor of protein synthesis
resulting from too rapid a turnover of mRNA in pro-
liferating cells! They gave chloramphenicol to 18 patients
'Dale received: 17 Nov,ember 1970.
tDepartment of Statistics, University of the Witwatersrand. Johannesburg.
6
suffering from parkinsonism. They claimed that 'nearly all'
patients improved and they interpreted this as due to in-
hibition of abnormal protein synthesis in the nigral neu-
rones.
Review of the Literature
Schwab et al.' were the first authors to publish an account
of the effect of amantadine in parkinsonism. They found 66%
of a group of 163 patients with parkinsonism exhibited improve-
ment in akinesia, rigidity and tremor while receiving amanta-
dine hydrochloride. Improvement was maintained in 58 % for
a period of 3 - 8 months. The maximum daily dose was 200
mg. Patients helped by amantadine were also helped by L-dopa
and in one patient the combination of amantadine and L-dopa
seemed beneficial. Side-effects occurred in 22 % of patients and
consisted of restlessness. insomnia, abdominal uneasiness, dizzi-
ness, depression, confusion and, in a few cases, hallucinations.
In most cases side-effects were controlled by reducing the dose
of amantadine or of concomitant medication.
Parkes et al.' carried out a double-blind cross-over trial of
amantadine. Dosage was 200 mg daily, given for 2 weeks.
Thirty-seven outpatients with parkinsonism were invited to take
part in the trial and 35 completed it. Patients were included
irrespective of age, sex. duration of symptoms or extent of
disability, provided no other neurological disorder was manifest.
The parkinsonism was thought to be of idiopathic origin in
the majority of patients, and of postencephalitic or cerebro-
vascular origin in the remainder.
All 35 patients who completed the trial expressed 'a highly
significant preference for amantadine'. Features of history
and examination were assessed by means of a standard
questionnaire and all symptoms and signs showed a significant
improvement on amantadine except for the patients' own
assessment of walking ability and the observers' assessment of
rigidity. Parkes et al. found that the degree of improvement
was not related to sex, age, duration or severity of disease.
previous thalamolysis or concurrent medication. They found
the drug to be free of side-effects and well tolerated by all
patients undergoing the trial.
MiIJac et al.' reported the effects of amantadine given con-
tinuously for 3 months to 32 patients with idiopathic parkin-
sonism. The patients were assessed at 3-weekly intervals.
Amantadine was added to concomitant medication, the dose
being gradually increased from 100 mg to 400 mg daily if re-
quired. Unfortunately, the authors do not give the precise
criteria for increasing the dosage.
Five patients withdrew because of side-effects; these consisted
of insomnia, nightmares and, in one patient. confusion with
hallucinations. All side-effects disappeared on discontinuing
amantadine. The authors found that increasing the dose of
amantadine above 200 mg daily sometimes resulted in further
improvement. contrary to the experience of Schwab et al.'
They concluded that the results of the trial were 'disappointing.
since in no instance could improvement be described as drama-
tic'. Th" improvement noted was a reduction in akinesia in 19
out of 27 patients.
Fieschi et al." carried out a double-blind cross-over trial of
amantadine in 20 patients with parkinsonism. They concluded
that amantadine has a prompt antiparkinsoni'\n effect. with
'significant improvement' in rigidity and an absence of side-
effects. They are currently comparing the effects of amantadine
with those of L-dopa in the same group of patients.
MATERIAL AND METHODS
Our trial was carried out on 23 patients, 10 of whom were
female, taken consecutively from the neurology outpatient
department. Ages ranged f:-om 51 to 74 years with an




Fig. I. Influence of amantadine on handwriting.
L
The neurological scores were assessed as follows: In
analysing the data, 3 assumptions were made:
(a) The effect of the 2 drugs (i.e. amantadine and
placebo) are independent. In practical terms, this means
that the assumption was made that the drugs take imme-
diate effect and are not retained in the body.
(b) A patient with severe parkinsonism is as likely to
show the same amount of improvement (or deterioration)
as a patient with a lesser degree of parkinsonism. Although
this is clinically unlikely, this assumption is a necessary
prerequisite of statistical analysis.
(c) As was obvious from the scores relating to patients
only on drug or only on placebo, there is a variation
within each patient which could not be estimated due to
the brevity of the exposure period; hence the ~ssumption
is made that the score obtained by each patient is due
to the drug or placebo and not to his own individual
variation.
a glued feeling' when describing their gait. Seven reported
that they felt more cheerful. A 58-year-old woman reported
that within 2 days of starting the capsules she was able
to climb stairs completely unaided for the first time in
4 years. All patients who felt better did so within 48 hours
of starting one of the test bottles.
Objectively there appeared to be improvement in rigi-
dity, tremor at rest, initiation of movements and blinking.
The elevation of mood was striking in 7 cases. Cine-films
were successful in some cases of highlighting improvement
in movement. Of the many handwriting specimens taken
during the trial, two comparisons are shown, from two
patients, taken a week apart (Fig. 1).
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Side-Effects
Dizziness was reported in 8 patients, in 7 of whom
cerebrovascular disease had been diagnosed. Three patients
complained of headache, one of muzziness and one of
increased irritability. No patient regarded these symptoms










of (0-0) N T OBS
Initiating movements 6 9 8
Rigidity 1 14 13
Tremor at rest 2 13 10
Tremor action 4 11 7
Depression 9 6 5
Alertness 5 8 6
Gait 7 7 5
Blinking 0 15 8
Voice/speech 11 4 3
Jaw tremor 7 6 1
Arm swing 5 10 5
Salivation 13 2 2
Convergence 4 11 3
Sleep 11 4 2
When K>N no statis~ical test wa~ applied as the majority of patients had
':::J~~o~:~e~b:;11:ed~lth amantadme and placebo, therefore no probability
K=Number of (0'0), Le. number of patients who showed no marked
difference between amantadine and placebo.
N= 15-K,. Le. there were 15 'pati~nts not solely on amantadine or placebo.
TOBs=patIents observed showmg Improvements on amantadine.
'Significant at I % level, Le. 1 chance out of 100 of obtaining this result
by chance alone.
tSignificant at 5% level, Le. 5 chances out of 100 of obtaining this result
by chance alone.
To interpret the table c~nsider for example. the symptom, 'Initiating
movements. Out of. b pati~nts under observatIon, sbe (K=6) improved
equally Wlth amantadme as W!th placebo. Out of nine patients (N=9), eight
(ToBs=~). show~ a greater Improvement on amantadine. The probability
of obtamIng thIS result by chance alone, assuming there is no difference
between amantadine and placebo, is 0,196, i.e. about 1 chance out of 5.
average age of 62·5 years. The duration of manifest
parkinsonism ranged from 2 years to 7 years with an
average of 4·6 years. The severity varied from unilateral
lower-limb rigidity to a severely incapacitated non-
ambulatory state. In 12 patients cerebral arteriosclerosis
had been diagnosed, in one patient the parkinsonism was
thought to be postencephalitic, and in 10 cases the aetiology
was unknown. None of the patients had surgical treatment
for parkinsonism.
All patients were on conventional antiparkinsonian medi-
cation, which included one or a combination of the follow-
ing preparations: trihexiphenidyl (Artane), orphenadrine
(Disipal), procyclidine (Kemadrin) and biperiden (Akine-
ton). Five patients were on antihypertensive medication.
Each patient was given a supply of test capsules identi-
fied only by a code number, the code being kept secret by
the drug company. The patients were instructed to take one
capsule in the morning and one at midday, in addition to
their usual medication which was not altered. The patients
were informed that the medical staff did not know whether
drug or placebo was used. After 2 weeks patients were
given another bottle of identical-looking capsules (cross-
over).
Clinical assessment of symptoms and signs was carried
out by 2 clinicians at weekly intervals for 5 weeks. Care
was taken to standardize test conditions and all assessments
took place between 9 a.m. and 12 noon. The assessment
consisted of scoring 14 symptoms on a scale of 0 - 4 (Table
I). Patients were also observed and cinefilmed, while
TABLE 1. RESULTS OF CLINICAL TESTS
writing, stringing beads, manipulating pegs in pegboards,
rising from a sitting position .from a chair and sudden
changes in direction while walking.
RESULTS
Clinical
Of the 23 patients, 16 reported subjective improvement
ranging from mild to marked; 4 patients reported 'less of
DISCUSSION
The results of this trial show that, both clinically and statis-
tically, amantadine hydrochloride appears to be of value
in the treatment of parkinsonism. Improvement was noted
in akinesia and rigidity and, to a lesser extent, tremor. A
striking feature in our trial has been the rapidity of effect
of amantadine. When it was effective it was so within 48
hours. This was noted by Schwab et al.,' Parkes er al.-
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and Fieschi et al:
Our findings suggest that amantadine is relatively free
of side-effects. Parkes el aI: found side-effects more
common with placebo treatment ·but Fieschi et al.' found
them to be absent. However, Schwab et al.' reported quite
marked side-effects in some 22% of patients. Millac et al.'
reported effects severe enough to compel 5 of 32 patients
to withdraw from the trial. These, however, used amanta-
dine in doses varying from 100 mg to 400 mg daily and
claimed some further improvement, but did not elaborate
on this. In other trials the maximum dose administered
was 200 mg daily except for Schwab et al.' who increased
the dose to 300 mg daily in some patients. They reported
that 'it soon became apparent that there was no increase
in benefits from doses greater than 200 mg per day'. The
possibility of amantadine potentiating the effects of con-
comitant medication or vice versa has been raised"3,, and
it may be necessary to reduce the dosage of the 'conven-
tional' antiparkinsonian medication to eliminate side-effects.
To illustrate this, Schwab et al.' report a case of a 67-year-
old man who, after 3 weeks of tested amantadine therapy,
manifested hallucinations and confusion. They reported
that 'reducing the procyclidine and benztropine eliminated
these side-effects and the patient remained much improved'.
We wish to tbank Dr J. G. Burger, Medical Superintendem
of Groote Schuur Hospital, for permission to publish, and
Dr D. Jacobs, Medical Director, Ciba-Geigy, for assistance.
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ANGINA PECTORIS AND NORMAL CORONARY ANGIOGRAPHY*
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SUMMARY
Thirteen cases of angina pectoris Wilh normal coronary
arteriograms are described, 9 of which occurred in females.
A 14th patient, a woman aged 28, had angina pectoris with
an abnormal cardiogram and a positive after-effon lest.
Postmortem examination showed complelely normal
coronary arteries, and there was no cardiac muscle or valve
pathology. The pathophysiological basis for lhe angina
pectoris in these cases must, we consider, still be regarded
as obscure.
In most patients with symptomatic or electrocardiographic
evidence of ischaemic heart disease, coronary artery ob-
struction or narrowing provides a pathophysiological basis
for the myocardial hypoxia. The pioneering and develop-
ment of selective cine-coronary angiography by Sones and
colleagues'" has made possible the correlation of clinical
syndromes of arterial obstruction during life.
Several angiographic studies have demonstrated that
obstruction can be shown in at least J major coronary
artery in most patients with angina pectoris, and often
disease of two or three vessels has been demonstrated.'"
The electrocardiogram in most patients is abnormal at rest
or on effort.
The demonstration of the wide distribution of coronary
artery disease in these patients is in keeping with earlier
reports on comparison between clinical and post~ortem
studies in coronary artery disease. These correlatIOns do
not necessarily apply in the presence of valvular or other
forms of organic heart disease.'o The problem of myo-
cardial infarction with normal coronary arteriograms has
been well discussed by Campeau."
In the large series of patients with coronary heart disease
*D::t.te received: 4 January ]971. An abstract of t~is paper aopeared i~
'Abstracts of Paoers of VI World Congress of CardIOlogy. London, 6· L
SeDtember 1970.'
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reported by Proudfit et al.," 2 - 5% had normal coronary
arteriograms, and in the series of Kemp et al." 8 % had
normal coronary arteriograms. In the latter series 62 %
were females. Angina with normal coronary arteries has
also been reported by other workers. H . n Whiting el al."
report a case of variant angina pectoris with normal
coronary arteriograms. We are reporting a significant
group of patients with angina pectoris without demon-
strable heart disease, who do not show abnormalities of
the coronary arteries on the angiocardiogram.
MATERIAL
For the past 8 years we have performed selective coronary
angiography in patients for the elucidation of chest pain
and in the investigation of heart disease of uncertain aetio-
logy. Among these cases there have been I3 patients with
a history which we accepted as angina pectoris. Some had
superadded symptoms of anxiety and hyperventilation.
These I3 comprised 6 White females, 3 White males, 3
Coloured females and I Coloured male. Their ages ranged
from 26 to 53 years. None of the patients had diabetes
or hypertension. The Wassermann reaction when done was
negative. The blood cholesterol, when done, was within
the normal range. No patient had valve disease or cardio-
megaly The duration of the chest pain varied from 2
months to I J years in the patients when first seen in the
Cardiac Clinic.
A fourteenth case, a 28-year-old White female, is in-
cluded in this report. This patient had typical angina
pectoris. She had a story of 6 months' substernal chest
pain, burning in character across the chest, through to the
back, down the left arm, occurring on effort or after
emotion. There was a marked anxiety factor in her make-
up. She did not have selective coronary arteriography, but
the coronary arteries were studied at postmortem examina-
tion. Thus. of our total series, 70% were females.
